Kymera Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$67.85(as of Nov 28, 12:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Kymera Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$67.85
Ticker SymbolKYMR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees225
CountyUSA
Market Cap$4,882.5M

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics Inc In Our Stock Scanner

As of Nov 28, 2025
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.